Cabaletta Bio Q1 net loss widens as R&D costs rise

Cabaletta Bio

Cabaletta Bio

CABA

0.00


Overview

  • US cell therapy developer's Q1 net loss widened from prior year

  • Research and development expenses rose, while general and administrative costs declined yr/yr

  • Company raised $150 mln in gross proceeds from May 2026 registered direct offering


Result Drivers

  • R&D SPENDING - Higher research and development expenses contributed to wider Q1 net loss

  • PIPELINE PROGRESS - Company advanced pivotal trials and expanded manufacturing capabilities for rese-cel


Company press release: ID:nGNX1gY0gH


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$0.39


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Cabaletta Bio Inc is $13.50, about 276% above its May 13 closing price of $3.59


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.